Clinical Trial Update: OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 [Phase 2, Phase 3]

View source ↗

Summary

Open-label extension (OLE) of the Phase 2b/3 ANAVEX2-73-AD-004 study in Alzheimer disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ANAVEX2-73 (blarcamesine)

Snippet

Sponsor: Anavex Life Sciences Corp. | Conditions: Alzheimer Disease | Phase 2, Phase 3 | Status: COMPLETED